New to peptides? Start with the foundations ->
The dad-test answer
Branded GLP-1s (Mounjaro, Zepbound, Ozempic, Wegovy) are FDA-approved and have full clinical-trial backing. Compounded versions are produced by 503A and 503B compounding pharmacies, were legal during the FDA's official drug-shortage list, and that shortage status changed in 2024 to 2025. Branded is the safer regulatory and quality answer; compounded was the cost-effective answer during the shortage. Check current FDA shortage-list status before making a decision.
Who wins for what
| Use case | Who wins, and why |
|---|---|
| regulatory safety, FDA approval |
branded Mounjaro, Zepbound, Ozempic, and Wegovy are FDA-approved with full clinical-trial backing and post-market surveillance. |
| cost (when shortage status allows compounding) |
compounded Compounded tirzepatide and semaglutide typically run 50-80% less than branded list price; insurance coverage often makes branded competitive. |
| quality control, batch consistency |
branded FDA-supervised manufacturing standards; compounded products vary by pharmacy and require scrutiny of USP standards and COAs. |
| access during commercial supply tightness |
compounded (when on shortage list) FDA Section 503A/503B authority allows compounding when a drug is on the official shortage list; status changed in 2024. |
What the head-to-head data shows
Compounding pharmacies operate under FDA Sections 503A and 503B - 503A pharmacies compound for individual patient prescriptions; 503B outsourcing facilities operate under tighter cGMP-equivalent rules. The FDA placed both tirzepatide and semaglutide on the official drug shortage list during 2022 to 2024, which legally permitted large-scale compounding of these molecules. The FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage in February 2025 - which materially restricted legal compounding for both molecules. The FDA has also warned that compounded GLP-1 products carry risks from non-pharmaceutical-grade APIs, dosing errors, and lack of post-market surveillance. Branded products carry FDA-supervised cGMP backing and the full SURMOUNT, SURPASS, STEP, and SUSTAIN trial record.
Our honest call
The compounded vs branded calculus changed in 2024 to 2025. While the FDA shortage list permitted compounding, compounded tirzepatide and semaglutide were a legal and significantly cheaper option for patients without insurance coverage. With the shortage status resolved, the legal authority for large-scale compounding has tightened - which means a reader needs to check the current FDA list at decision time, not assume the compounded option is still on the table. Quality varies by pharmacy regardless: any compounded product needs a Certificate of Analysis (third-party purity test) on the batch and a 503B-licensed source. Branded is the safer and simpler answer when insurance covers it. Read the GLP-1 starter guide before the telehealth call.
Sources and citations
- FDA Sections 503A and 503B compounding regulations
- FDA tirzepatide shortage resolution announcement (October 2024)
- FDA semaglutide shortage resolution announcement (February 2025)
- FDA warning on compounded GLP-1 risk profile (2024)
- Aronne et al., SURMOUNT-5 head-to-head, NEJM 2025 (PMID 40374016)
Where to go next
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.
Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine. None of this replaces a doctor. Peptides are gray-market in the US for most uses. Talk to a real prescriber before you change anything.